Highland Capital Management LP cut its stake in Humana Inc (NYSE:HUM) by 40.4% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,170 shares of the insurance provider’s stock after selling 2,830 shares during the period. Highland Capital Management LP’s holdings in Humana were worth $1,241,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. FMR LLC lifted its position in Humana by 12.7% in the second quarter. FMR LLC now owns 12,212,514 shares of the insurance provider’s stock valued at $3,634,811,000 after acquiring an additional 1,374,030 shares during the last quarter. BlackRock Inc. lifted its position in Humana by 1.7% in the first quarter. BlackRock Inc. now owns 12,186,387 shares of the insurance provider’s stock valued at $3,276,068,000 after acquiring an additional 198,588 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in Humana by 0.8% in the first quarter. Dimensional Fund Advisors LP now owns 1,564,251 shares of the insurance provider’s stock valued at $420,503,000 after acquiring an additional 11,915 shares during the last quarter. Acadian Asset Management LLC lifted its position in Humana by 7.6% in the second quarter. Acadian Asset Management LLC now owns 1,324,681 shares of the insurance provider’s stock valued at $394,262,000 after acquiring an additional 93,021 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA lifted its position in Humana by 3.5% in the second quarter. Massachusetts Financial Services Co. MA now owns 768,245 shares of the insurance provider’s stock valued at $228,653,000 after acquiring an additional 26,303 shares during the last quarter. 93.00% of the stock is owned by hedge funds and other institutional investors.

NYSE HUM opened at $332.88 on Wednesday. The stock has a market cap of $46.44 billion, a P/E ratio of 28.43, a PEG ratio of 1.68 and a beta of 0.96. Humana Inc has a 52-week low of $231.90 and a 52-week high of $337.56. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.43 and a quick ratio of 1.43.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, August 1st. The insurance provider reported $3.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.79 by $0.17. The firm had revenue of $14.26 billion during the quarter, compared to analysts’ expectations of $14.16 billion. Humana had a net margin of 2.48% and a return on equity of 17.43%. During the same period in the prior year, the company posted $3.49 earnings per share. sell-side analysts predict that Humana Inc will post 14.18 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, October 26th. Investors of record on Friday, September 28th will be issued a dividend of $0.50 per share. The ex-dividend date is Thursday, September 27th. This represents a $2.00 annualized dividend and a yield of 0.60%. Humana’s dividend payout ratio is currently 17.08%.

In other Humana news, insider Elizabeth D. Bierbower sold 3,092 shares of the company’s stock in a transaction dated Thursday, August 16th. The shares were sold at an average price of $330.00, for a total transaction of $1,020,360.00. Following the transaction, the insider now directly owns 14,289 shares in the company, valued at $4,715,370. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Jody L. Bilney sold 27,461 shares of the company’s stock in a transaction dated Friday, June 15th. The stock was sold at an average price of $306.46, for a total transaction of $8,415,698.06. Following the transaction, the insider now owns 11,467 shares in the company, valued at $3,514,176.82. The disclosure for this sale can be found here. Insiders have sold 61,213 shares of company stock valued at $19,081,052 over the last three months. 0.60% of the stock is currently owned by corporate insiders.

A number of brokerages have recently commented on HUM. Bank of America upped their target price on shares of Humana from $338.00 to $375.00 and gave the company a “buy” rating in a report on Thursday, August 2nd. Piper Jaffray Companies upped their target price on shares of Humana from $326.00 to $350.00 and gave the company an “overweight” rating in a report on Friday, July 6th. ValuEngine cut shares of Humana from a “buy” rating to a “hold” rating in a report on Saturday, June 2nd. BMO Capital Markets upped their target price on shares of Humana from $328.00 to $355.00 and gave the company an “outperform” rating in a report on Monday, June 25th. Finally, Zacks Investment Research raised shares of Humana from a “hold” rating to a “buy” rating and set a $329.00 target price for the company in a report on Monday, May 28th. Six research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Humana has a consensus rating of “Buy” and a consensus price target of $328.94.

About Humana

Humana Inc is a health and well-being company focused on making it easy for people to achieve best health. Its strategy integrates care delivery, the member experience, and clinical & consumer insights to encourage engagement, behavior change, proactive clinical outreach, and wellness for the people.

Recommended Story: NASDAQ Stock Market Explained

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.